Currently available only within Phase 3 clinical trials, retatrutide simultaneously activates GLP-1, GIP, and glucagon receptors, distinguishing it from approved therapies such as semaglutide and tirzepatide
Still, a clinician may also consider cardiovascular disease, diabetes treatment, sleep apnea, previous response, gastrointestinal tolerance, pregnancy plans, current medicines, access, and whether treatment can be continued
Managing side effects during dose escalation Gastrointestinal side effects are the primary challenge during retatrutide dose escalation
Abstracts, reviews, and articles on other disorders than pain were excluded
Data in (b,c) were analyzed by 1-way ANOVA with Bonferroni multiple comparison test
Q4: How does microdosing GLP-1 differ from full-dose use in a medical weight-loss context